請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61218完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤 | |
| dc.contributor.author | Shiu-Ling Li | en |
| dc.contributor.author | 李煦羚 | zh_TW |
| dc.date.accessioned | 2021-06-16T10:53:52Z | - |
| dc.date.available | 2018-09-24 | |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-09 | |
| dc.identifier.citation | Ambs, S., Hussain, S.P., and Harris, C.C. (1997). Interactive effects of nitric oxide
and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 11, 443-448. Ames, B.N., and Gold, L.S. (1997). The causes and prevention of cancer: gaining perspective. Environmental health perspectives 105 Suppl 4, 865-873. Arthur, J.C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123. Austin, C.A., Sng, J.H., Patel, S., and Fisher, L.M. (1993). Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochimica et biophysica acta 1172, 283-291. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C., and Liu, L.F. (2007). Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proceedings of the National Academy of Sciences of the United States of America 104, 11014-11019. Baker, N.M., Rajan, R., and Mondragon, A. (2009). Structural studies of type I topoisomerases. Nucleic acids research 37, 693-701. Balkwill, F., Charles, K.A., and Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell 7, 211-217. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252. Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J.M., Lukas, C., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870. Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., and Freeman, B.A. (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proceedings of the National Academy of Sciences of the United States of America 87, 1620-1624. Berger, J.M., Gamblin, S.J., Harrison, S.C., and Wang, J.C. (1996). Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232. Bove, P.F., and van der Vliet, A. (2006). Nitric oxide and reactive nitrogen species in airway epithelial signaling and inflammation. Free radical biology & medicine 41, 515-527. Brinkmann, V., Davis, M.D., Heise, C.E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. The Journal of biological chemistry 277, 21453-21457. Champoux, J.J. (2001). DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry 70, 369-413. Colotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081. Cornarotti, M., Tinelli, S., Willmore, E., Zunino, F., Fisher, L.M., Austin, C.A., and Capranico, G. (1996). Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Molecular pharmacology 50, 1463-1471. Cuevas-Ramos, G., Petit, C.R., Marcq, I., Boury, M., Oswald, E., and Nougayrede, J.P. (2010). Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 107, 11537-11542. Daroui, P., Desai, S.D., Li, T.K., Liu, A.A., and Liu, L.F. (2004). Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. The Journal of biological chemistry 279, 14587-14594. de Visser, K.E., Eichten, A., and Coussens, L.M. (2006). Paradoxical roles of the immune system during cancer development. Nature reviews Cancer 6, 24-37. Dinerman, J.L., Dawson, T.M., Schell, M.J., Snowman, A., and Snyder, S.H. (1994). Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America 91, 4214-4218. Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine 315, 1650-1659. Eaden, J.A., Abrams, K.R., and Mayberry, J.F. (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535. Egeblad, M., Nakasone, E.S., and Werb, Z. (2010). Tumors as organs: complex tissues that interface with the entire organism. Developmental cell 18, 884-901. Gloeckler Ries, L.A., Reichman, M.E., Lewis, D.R., Hankey, B.F., and Edwards, B.K. (2003). Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. The oncologist 8, 541-552. Goodman, J.E., Hofseth, L.J., Hussain, S.P., and Harris, C.C. (2004). Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environmental and molecular mutagenesis 44, 3-9. Haffner, M.C., Aryee, M.J., Toubaji, A., Esopi, D.M., Albadine, R., Gurel, B., Isaacs, W.B., Bova, G.S., Liu, W., Xu, J., et al. (2010). Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature genetics 42, 668-675. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. Hobbs, A.J., Higgs, A., and Moncada, S. (1999). Inhibition of nitric oxide synthase as a potential therapeutic target. Annual review of pharmacology and toxicology 39, 191-220. Hofseth, L.J., Saito, S., Hussain, S.P., Espey, M.G., Miranda, K.M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S.P., et al. (2003). Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America 100, 143-148. Hotamisligil, G.S. (2006). Inflammation and metabolic disorders. Nature 444, 860-867. Hussain, S.P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W.P., Shields, P.G., Ham, A.J., Swenberg, J.A., Marrogi, A.J., et al. (2000). Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer research 60, 3333-3337. Hussain, S.P., Hofseth, L.J., and Harris, C.C. (2003). Radical causes of cancer. Nature reviews Cancer 3, 276-285. Ioanoviciu, A., Antony, S., Pommier, Y., Staker, B.L., Stewart, L., and Cushman, M. (2005). Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. Journal of medicinal chemistry 48, 4803-4814. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K.R., Tanabe, K., and Andoh, T. (1991). Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer research 51, 4909-4916. Itzkowitz, S.H., and Yio, X. (2004). Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. American journal of physiology Gastrointestinal and liver physiology 287, G7-17. Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recognition. Annual review of immunology 20, 197-216. Ju, B.G., Lunyak, V.V., Perissi, V., Garcia-Bassets, I., Rose, D.W., Glass, C.K., and Rosenfeld, M.G. (2006). A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312, 1798-1802. Ju, B.G., and Rosenfeld, M.G. (2006). A breaking strategy for topoisomerase IIbeta/PARP-1-dependent regulated transcription. Cell cycle 5, 2557-2560. Kobzik, L., Bredt, D.S., Lowenstein, C.J., Drazen, J., Gaston, B., Sugarbaker, D., and Stamler, J.S. (1993). Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. American journal of respiratory cell and molecular biology 9, 371-377. Kuper, H., Adami, H.O., and Trichopoulos, D. (2000). Infections as a major preventable cause of human cancer. Journal of internal medicine 248, 171-183. Laponogov, I., Sohi, M.K., Veselkov, D.A., Pan, X.S., Sawhney, R., Thompson, A.W., McAuley, K.E., Fisher, L.M., and Sanderson, M.R. (2009). Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature structural & molecular biology 16, 667-669. Larsen, A.K., Escargueil, A.E., and Skladanowski, A. (2003). Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology & therapeutics 99, 167-181. Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature 396, 643-649. Li, T.K., Chen, A.Y., Yu, C., Mao, Y., Wang, H., and Liu, L.F. (1999). Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress. Genes & development 13, 1553-1560. Li, T.K., and Liu, L.F. (2001). Tumor cell death induced by topoisomerase-targeting drugs. Annual review of pharmacology and toxicology 41, 53-77. Lowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. Nature 432, 307-315. Mantovani, A. (2005). Cancer: inflammation by remote control. Nature 435, 752-753. Morham, S.G., Kluckman, K.D., Voulomanos, N., and Smithies, O. (1996). Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Molecular and cellular biology 16, 6804-6809. Nakane, M., Schmidt, H.H., Pollock, J.S., Forstermann, U., and Murad, F. (1993). Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS letters 316, 175-180. Nitiss, J.L. (1998). Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochimica et biophysica acta 1400, 63-81. Nitiss, J.L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews Cancer 9, 338-350. O'Dell, T.J., Huang, P.L., Dawson, T.M., Dinerman, J.L., Snyder, S.H., Kandel, E.R., and Fishman, M.C. (1994). Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 265, 542-546. Pekarek, L.A., Starr, B.A., Toledano, A.Y., and Schreiber, H. (1995). Inhibition of tumor growth by elimination of granulocytes. The Journal of experimental medicine 181, 435-440. Prehn, R.T. (1972). The immune reaction as a stimulator of tumor growth. Science 176, 170-171. Rachmilewitz, D., Stamler, J.S., Bachwich, D., Karmeli, F., Ackerman, Z., and Podolsky, D.K. (1995). Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 36, 718-723. Radi, R., Beckman, J.S., Bush, K.M., and Freeman, B.A. (1991). Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Archives of biochemistry and biophysics 288, 481-487. Raingeaud, J., Gupta, S., Rogers, J.S., Dickens, M., Han, J., Ulevitch, R.J., and Davis, R.J. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. The Journal of biological chemistry 270, 7420-7426. Roder, D.M. (2002). The epidemiology of gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 5 Suppl 1, 5-11. Rowley, J.D. (1998). The critical role of chromosome translocations in human leukemias. Annual review of genetics 32, 495-519. Saleh, M., and Trinchieri, G. (2011). Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nature reviews Immunology 11, 9-20. Sanada, Y., Mizushima, T., Kai, Y., Nishimura, J., Hagiya, H., Kurata, H., Mizuno, H., Uejima, E., and Ito, T. (2011). Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PloS one 6, e23933. Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G., and Wallace, J.L. (2007). Resolution of inflammation: state of the art, definitions and terms. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21, 325-332. Shibata, H., Toyama, K., Shioya, H., Ito, M., Hirota, M., Hasegawa, S., Matsumoto, H., Takano, H., Akiyama, T., Toyoshima, K., et al. (1997). Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278, 120-123. Tanabe, K., Ikegami, Y., Ishida, R., and Andoh, T. (1991). Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer research 51, 4903-4908. Vane, J.R., Mitchell, J.A., Appleton, I., Tomlinson, A., Bishop-Bailey, D., Croxtall, J., and Willoughby, D.A. (1994). Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proceedings of the National Academy of Sciences of the United States of America 91, 2046-2050. Vos, S.M., Tretter, E.M., Schmidt, B.H., and Berger, J.M. (2011). All tangled up: how cells direct, manage and exploit topoisomerase function. Nature reviews Molecular cell biology 12, 827-841. Walker, J.V., and Nitiss, J.L. (2002). DNA topoisomerase II as a target for cancer chemotherapy. Cancer investigation 20, 570-589. Wang, J.C. (1996). DNA topoisomerases. Annual review of biochemistry 65, 635-692. Wang, J.C. (2002). Cellular roles of DNA topoisomerases: a molecular perspective. Nature reviews Molecular cell biology 3, 430-440. Willmore, E., Frank, A.J., Padget, K., Tilby, M.J., and Austin, C.A. (1998). Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Molecular pharmacology 54, 78-85. Wilstermann, A.M., and Osheroff, N. (2003). Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Current topics in medicinal chemistry 3, 321-338. Wu, C.C., Li, T.K., Farh, L., Lin, L.Y., Lin, T.S., Yu, Y.J., Yen, T.J., Chiang, C.W., and Chan, N.L. (2011). Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333, 459-462. Xie, J., and Itzkowitz, S.H. (2008). Cancer in inflammatory bowel disease. World journal of gastroenterology : WJG 14, 378-389. Yang, Y.C., Chou, H.Y., Shen, T.L., Chang, W.J., Tai, P.H., and Li, T.K. (2013). Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis. Antioxidants & redox signaling 18, 1129-1140. Zhang, Y., Strissel, P., Strick, R., Chen, J., Nucifora, G., Le Beau, M.M., Larson, R.A., and Rowley, J.D. (2002). Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proceedings of the National Academy of Sciences of the United States of America 99, 3070-3075. Zingarelli, B., O'Connor, M., Wong, H., Salzman, A.L., and Szabo, C. (1996). Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. Journal of immunology 156, 350-358. Zuo, X., Peng, Z., Moussalli, M.J., Morris, J.S., Broaddus, R.R., Fischer, S.M., and Shureiqi, I. (2009). Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. Journal of the National Cancer Institute 101, 762-767. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61218 | - |
| dc.description.abstract | 潰瘍性結腸炎（ulcerative colitis）為一種腸道發炎疾病（inflammatory bowel diseases），其患者深受氮化壓力（nitrosylation stress）、腸道組織損傷及基因不穩定的影響，故較正常人更易形成大腸直腸癌；所以，我們想更進一步探討在發炎的情況下，氮化壓力的產生和癌症發生之間的交互作用與分子機制。實驗室先前的研究顯示氧化壓力具有引起第二型拓樸異構酶切割複合物產生的能力，進而導致DNA 斷裂、突變及細胞死亡；實驗室近期研究顯示一氧化氮可引起氮化壓力、產生第二型拓樸異構酶切割複合物（topoisomerase II cleavable complex, TOP2cc）及拓樸異構酶IIβ亞型之依賴性癌症；然而，第二型拓樸異構酶媒介之DNA損傷的活化是否在潰瘍性結腸炎所造成的組織損傷及進一步的癌症產生之間扮演不可或缺的角色是值得被進一步探討的。為了研究上述主題，我們利用化合物DSS引起之小鼠腸道發炎模式、免疫組織染色及藥物來探討在發炎的組織內，氮化壓力及DNA損傷的表現程度。我們觀察到在腸道發炎的小鼠內，第二型一氧化氮合成酶（nitric oxide synthase II, NOS2）大量表現，並且和巨噬細胞的表現趨勢一致，說明巨噬細胞的NOS2表現可能與DSS引起小鼠腸道發炎之病理進程有關；此外，我們也觀察到腸道發炎小鼠具有體重減輕及腸道縮短這些腸道發炎的特徵。我們利用第二型一氧化氮合成酶缺失的小鼠（NOS2-/-）探討氮化壓力是否在腸道發炎中扮演重要角色；我們觀察到體重減輕及腸道縮短在第二型一氧化氮合成酶缺失小鼠是較為緩解的；此外，我們也觀察到DNA損傷在第二型一氧化氮酶缺失小鼠也是減少的。以上結果顯示，對於腸道發炎所引起的病理現象及DNA損傷，一氧化氮是重要因子；且巨噬細胞在腸道發炎組織內為主要的一氧化氮來源。接著，我們進一步利用第二型拓樸異構酶針對性藥物來探討第二型拓樸異構酶是否可能在氮化壓力所引起的DNA損傷中扮演角色。我們發現在腸道發炎的小鼠內，第二型拓樸異構酶抑制型藥物（ICRF-193)具有減少DNA損傷的能力；以上結果顯示，第二型拓樸異構酶具有媒介發炎時氮化壓力所引起DNA損傷的能力。進一步研究第二型拓樸異構酶是否與發炎與發炎相關之癌症發生有關，我們利用腺病毒載體（adenoviral vector）表達Cre 重組酶（Cre-recombinase）於老鼠之大腸直腸細胞，將來將利用此方法來製造拓樸異構酶IIβ亞型缺失之TOP2βflox/flox 老鼠供研究拓樸異構酶IIβ亞型是否與發炎與發炎相關之癌症發生有關。 | zh_TW |
| dc.description.abstract | Patients with ulcerative colitis (UC), an inflammatory bowel disease suffered from nitrosylation stress, colon tissue damage and genomic instability, are prone to tumor formation. Here, we have investigated the contributions of inflammation-associated nitrosylation stress to UC pathogenesis and its underlying mechanisms. Previously, we have reported that oxidative stress induces topoisomerase II cleavable complex (TOP2cc) formation and subsequently leading to DNA breakage, mutagenesis and cell death. Moreover, we have also recently shown that nitric oxide (NO) induces nitrosylation stress, TOP2cc formation and TOP2β-dependent tumor formation. However, it remains to be determined whether NO and TOP2-mediated DNA damage plays an important role in UC-associated tissue damage and cancer development. To address this, immunohistochemistry (IHC) approach was first used to examine the expression of inducible nitric oxide synthase (NOS2, indicative of NO production) and γ-H2AX (indicative of DNA breakage) in colon of mice suffered from dextran sodium sulfate (DSS)-induced UC. Consistent with previous studies, we observed an increase in NOS2 expression and macrophage infiltration in the colon tissue samples from DSS-treated mice compared to control mice. In addition, we found that DSS induced concentration-dependent loss in body weight and shortening of colon length. Consistent with the notion that NO plays an important role in the pathogenesis of DSS-induced UC, all the above DSS-induced phenotypes are much relieved in the NOS2 knockout (NOS2-/-) mice. Furthermore, our results revealed for the first time that γ-H2AX signal is much higher in WT mice than NOS2-/- mice suggesting that nitrosylation stress which is responsible for DSS-activated DNA damage response and subsequent tissue damage. Further usage of TOP2-targeting drugs, VP-16 and ICRF-193, are used to determine the role of TOP2 in nitrosylation stress-induced DNA damage. Mice treated with ICRF-193 showed reduced DNA damage compared with DMSO-treated mice under DSS
treatment with any significant influences on body-weight loss, colon-length shortening and inflammatory score. Together, our results suggest that TOP2 mediates nitrosylation stress-induced DNA damage. Future investigation by using the tissue-specific knockout of TOP2βflox/flox mice were needed to determine the role of TOP2β in nitrosylation stress as well as associated mutagenic and carcinogenic activity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T10:53:52Z (GMT). No. of bitstreams: 1 ntu-102-R00445120-1.pdf: 3388516 bytes, checksum: 858d0be022ebab0769203c19bddab84f (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 口試委員審定書 .......................................................................................................................i
ACKNOWLEDGEMENTS .............................................................................................. ii 中文摘要............................................................................................................................iii ABSTRACT ........................................................................................................................v CONTENTS ..................................................................................................................... vii INTRODUCTION ............................................................................................................. 1 1. Inflammation.............................................................................................................. 1 1.1 Inflammation and carcinogenesis .......................................................................... 1 1.2 Inflammation, DNA damage and genomic instability ........................................... 3 1.2.1 Colitis-associated colorectal cancer.............................................................. 3 1.2.2 Nitric oxide synthase (NOS)......................................................................... 5 1.2.3 Nitrosylation stress and DNA damage.......................................................... 6 1.3 DNA damage and carcinogenesis .......................................................................... 7 2. DNA topoisomerases.................................................................................................. 8 2.1 Type I DNA topoisomerases ................................................................................ 10 2.2 Type II DNA topoisomerases............................................................................... 11 2.3 The importance of DNA topoisomerases-targeting drugs in cancer therapy ....... 12 2.4 The role of RNOS in topoisomerase-mediated DNA damage ............................. 13 2.4.1 ROS induces topoisomerases-mediated DNA damage ............................... 14 2.4.2 TOP2-mediated DNA cleavage and mutagenesis activated by nitric oxide during inflammation ........................................................................ 15 SPECIFIC AIMS ............................................................................................................. 16 MATERIALS AND METHODS .................................................................................... 17 1. Materials ................................................................................................................... 17 - Chemicals .................................................................................................................... 17 - Antibodies ................................................................................................................... 17 - Mouse strains .............................................................................................................. 17 2. Methods .................................................................................................................... 18 - Induction of experimental colitis ................................................................................ 18 - Evaluation of colonic damage ..................................................................................... 18 - Histopathological analysis .......................................................................................... 18 - Immunohistochemistry staining (IHC) and quantification analyses of IHC images .. 19 - TOP2-targeting drugs treatment .................................................................................. 20 - Adenovirus amplification ............................................................................................ 20 - Adenovirus infection of mice colon ............................................................................ 21 - Frozen tissue sections preparation............................................................................... 21 - Frozen tissue sections staining .................................................................................... 22 - Statistical analysis ....................................................................................................... 22 RESULTS ......................................................................................................................... 23 - Dextran sulfate sodium (DSS) induced a concentration-dependent loss in body weight and shortening of colon length in mice: the chemical-induced ulcerative colitis (UC) mouse model. .................................................................................................................. 23 - Characterization of the DSS-induced UC in mice: DSS also induced concentration-dependent increases in epithelial erosion, crypt abcesses, mucin depletion and cellular infiltration in colon of treated mice ............................................. 24 - Elevated levels of γ-H2AX, NOS2 and F4/80 expression in the colon tissue samples from DSS-treated mice compared to those of control mice ............................................ 24 - DSS-induced body weight loss and shortening of colon length are much relieved in NOS2-/- mice, an indicative of the contribution of NOS2 and NO in the UC pathogenesis. ................................................................................................................... 26 - Inflammation scores including the goblet cells loss, epithelial cells damage and crypt distortion were much relieved in NOS2-/- mice treated with DSS than WT mice with UC ................................................................................................................................... 27 - The activation levels of γ-H2AX DNA damage signal in the colon tissue samples from DSS-treated mice were much relieved in NOS2-/- mice compared to those of WT mice ................................................................................................................................. 27 - The mice treated with ICRF-193 and VP-16 showed no significant difference of the body weight and colon length ......................................................................................... 28 - The mice treated with ICRF-193 and VP-16 showed no significant difference of the cellular infiltration, mucin depletion and crypt distortion (inflammation). .................... 29 - ICRF co-treatment significantly reduced both the VP-16- and DSS-activated γ-H2AX levels: the involvement of TOP2 in the DNA damage generated during the DSS-induced UC. ............................................................................................................ 30 - The adenovirus (Ad-CRE) successfully infected the colon epithelial cells in WT mice. ................................................................................................................................ 31 DISCUSSION ................................................................................................................... 32 FIGURES ......................................................................................................................... 35 - Figure 1 Dextran sulfate sodium (DSS) induced a concentration-dependent loss in body weight and shortening of colon length in mice: the chemical-induced ulcerative colitis (UC) mouse model ............................................................................................... 36 - Figure 2 Characterization of the DSS-induced UC in mice: DSS also induced concentration-dependent increases in epithelial erosion, crypt abcesses, mucin depletion and cellular infiltration in colon of treated mice ............................................. 37 - Figure 3 Elevated levels of γ-H2AX, NOS2 and F4/80 expression in the colon tissue samples from DSS-treated mice compared to those of control mice .............................. 38 - Figure 4 DSS induced concentration-dependent increase in γ-H2AX signals ................ 39 - Figure 5 DSS induced concentration-dependent increase in NOS2 and F4/80 expression in the colon tissue samples from DSS-treated mice ...................................... 40 - Figure 6 DSS-induced body weight loss and shortening of colon length are much relieved in NOS2-/- mice ................................................................................................. 41 - Figure 7 Inflammation scores were much relieved in NOS2-/- mice treated with DSS than WT mice with UC ................................................................................................... 42 - Figure 8 DSS induced concentration-dependent increase in γ-H2AX and F4/80 signals in the colon tissue samples from DSS-treated mice ........................................................ 43 - Figure 9 The activation levels of γ-H2AX DNA breakage signal in the colon tissue samples from DSS-treated mice were much relieved in NOS2-/- mice compared to those of WT mice ............................................................................................................ 44 - Figure 10 Under 3% DSS treatment, the macrophage marker, F4/80 showed no difference between WT and NOS2-/- mice ....................................................................... 45 - Figure 11 The mice treated with ICRF-193 showed no significant difference of the body weight and colon length under 3% DSS treatment ................................................ 46 - Figure 12 The mice treated with ICRF-193 showed no significant difference of the cellular infiltration, mucin depletion and crypt distortion (inflammation) ..................... 47 - Figure 13 ICRF co-treatment significantly reduced both the VP-16- and DSS-activated γ-H2AX levels: the involvement of TOP2 in the DNA damage generated during the DSS-induced UC ........................................................................... 48 - Figure 14 ICRF co-treatment significantly reduced both the VP-16- and DSS-activated γ-H2AX levels ......................................................................................... 49 - Figure 15 ICRF co-treatment didn't affect the NOS2 expression and macrophage recruitment ...................................................................................................................... 50 - Figure 16 The adenovirus (Ad-CRE) successfully infected the colon epithelial cells in WT mice .......................................................................................................................... 51 REFERENCES ................................................................................................................ 52 | |
| dc.language.iso | en | |
| dc.subject | 潰瘍性結腸炎 | zh_TW |
| dc.subject | 第二型一氧化氮合成?第二型拓樸異構?DNA 損傷 | zh_TW |
| dc.subject | 氮化壓力 | zh_TW |
| dc.subject | DNA damage | en |
| dc.subject | NOS2 | en |
| dc.subject | DNA topoisomerase | en |
| dc.subject | UC | en |
| dc.subject | nitrosylation stress | en |
| dc.title | 利用小鼠腸道發炎模式系統來探討拓樸酶在氮化壓力所引起的DNA損傷扮演的角色 | zh_TW |
| dc.title | The role of nitrosylation stress-induced topoisomerase-mediated DNA damage during inflammation in a colitis mouse model | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 賴逸儒,楊宏志 | |
| dc.subject.keyword | 第二型一氧化氮合成?第二型拓樸異構?DNA 損傷,氮化壓力,潰瘍性結腸炎, | zh_TW |
| dc.subject.keyword | NOS2,DNA topoisomerase,DNA damage,nitrosylation stress,UC, | en |
| dc.relation.page | 61 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-08-09 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 3.31 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。